Pharmacogenomics of aromatase inhibitors in postmenopausal breast cancer and additional mechanisms of anastrozole action

Aromatase inhibitors (AIs) reduce breast cancer recurrence and prolong survival, but up to 30% of patients exhibit recurrence. Using a genome-wide association study of patients entered on MA.27, a phase III randomized trial of anastrozole versus exemestane, we identified a single nucleotide polymorp...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:JCI Insight
Main Authors: Cairns, Junmei, Ingle, James N., Dudenkov, Tanda M., Kalari, Krishna R., Carlson, Erin E., Na, Jie, Buzdar, Aman U., Robson, Mark E., Ellis, Matthew J., Goss, Paul E., Shepherd, Lois E., Goodnature, Barbara, Goetz, Matthew P., Weinshilboum, Richard M., Li, Hu, Bari, Mehrab Ghanat, Wang, Liewei
Formato: Artigo
Idioma:Inglês
Publicado em: American Society for Clinical Investigation 2020
Assuntos:
Research Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC7455128/
https://ncbi.nlm.nih.gov/pubmed/32701512
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1172/jci.insight.137571
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados